TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$7.27 USD
+0.09 (1.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.13 -0.14 (-1.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
TScan Therapeutics, Inc. [TCRX]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Where the Brook Is Deep; State of Acute Myeloid Leukemia Treatment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
T-Plex-A Molecular Match-Making Service With Love for Patients and Hate for Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TScan?s TCR-T?s Continue to Assault Solid And Liquid Tumors; Reiterate Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Oncology Event: The Rise of PRAME-Targeted Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Heme/Solid Tumor Data Throughout 2024; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Batter Up; T-plex at the Plate, TSC-100/101 on Deck.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-100/TSC-101 Display?s Impressive Relapse-Free Levels (100%) with Complete Donor Chimerism
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-100/101 Data at ASH ?23 Continue to Trend Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A